Firebrick Pharma Limited · ASX:FRE

Stephen Francis Goodall received 18,000,000 Firebrick Pharma Limited shares as an award (Appendix 3Y, ASX)

Traded Nov 16, 2026 · Filed Nov 17, 2026

On Nov 16, 2026, Stephen Francis Goodall (Director) received 18,000,000 Firebrick Pharma Limited shares as an award. Filed Nov 17, 2026 (Appendix 3Y, ASX).

Awarded
18,000,000 shares
Role
Director

The filing in full

*Rule 3.19A.2*

Appendix 3Y

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entityFirebrick Pharma Limited
ABN64 157 765 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.

Name of DirectorStephen Francis Goodall
Date of last notice21 May 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Direct or indirect interestIndirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Rosemary Anne Goodall (Relevant Interest under Section 608(1)c of the Corporations Act)
Date of change16 November 2026
No. of securities held prior to changeBiotech Design Pty Ltd 30,326, 472 Ordinary fully paid shares S & R Goodall Super Pty Ltd 821,818 Ordinary fully paid shares
ClassUnlisted Options Expiring 16 November 2031 @ $0.06
Number acquired18,000,000
Number disposed-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil

---

No. of securities held after changeBiotech Design Pty Ltd 30,326, 472 Ordinary fully paid shares S & R Goodall Super Pty Ltd 821,818 Ordinary fully paid shares Rosemary Anne Goodall 18,000,000 Unlisted Options Expiring 16 November 2031 @ $0.06
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backApproved by members at the AGM held on 11 November 2026

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.

Detail of contractN/A
Nature of interestN/A
Name of registered holder (if issued securities)N/A
Date of changeN/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changedN/A
Interest acquiredN/A
Interest disposedN/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuationN/A
Interest after changeN/A
  • See chapter 19 for defined terms.

---

+
Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?No
If so, was prior written clearance provided to allow the trade to proceed during this period?-
If prior written clearance was provided, on what date was this provided?-
  • See chapter 19 for defined terms.
DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 16, 2026Unlisted Options Expiring 16 November 2031 @ $0.06Award18,000,000

Source

Download PDF · View original at ASX

Related